Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (5)
  • Open Access

    ARTICLE

    MicroRNA-133b Inhibits Proliferation, Cellular Migration, and Invasion via Targeting LASP1 in Hepatocarcinoma Cells

    Hui Li*, Zhigang Xiang*, Yan Liu*, Bin Xu*, Jianzhou Tang

    Oncology Research, Vol.25, No.8, pp. 1269-1282, 2017, DOI:10.3727/096504017X14850151453092

    Abstract MicroRNAs (miRs), a class of small noncoding RNAs, are key gene regulators through inducing translational repression or degradation of their target genes. However, the regulatory mechanism of miR-133b underlying hepatocellular carcinoma (HCC) growth and metastasis remains largely unclear. Here we found that miR-133b was significantly downregulated in HCC tissues and cell lines. Moreover, low miR-133b levels were significantly associated with the malignant progression of HCC. LASP1, upregulated in HCC tissues and cell lines, was then identified as a novel target of miR-133b in HCC HepG2 and Hep3B cells. Moreover, the increased expression of LASP1 was… More >

  • Open Access

    ARTICLE

    Overexpression of SASH1 Inhibits the Proliferation, Invasion, and EMT in Hepatocarcinoma Cells

    Ping He*, Hong-xia Zhang, Chang-yu Sun*, Chun-yong Chen, He-qing Jiang*

    Oncology Research, Vol.24, No.1, pp. 25-32, 2016, DOI:10.3727/096504016X14575597858609

    Abstract The SASH1 (SAM- and SH3-domain containing 1) gene, a member of the SLY (SH3 domain containing expressed in lymphocytes) family of signal adapter proteins, has been implicated in tumorigenesis of many types of cancers. However, the role and mechanism of SASH1 in the invasion and metastasis of hepatocarcinoma are largely unknown. In this study, we investigated the role and mechanism of SASH1 in the invasion and metastasis of hepatocarcinoma. Our results showed that SASH1 was lowly expressed in hepatocarcinoma cell lines. The in vitro experiments showed that overexpression of SASH1 inhibited the proliferation and migration/invasion More >

  • Open Access

    ARTICLE

    miR-122 Inhibits Hepatocarcinoma Cell Progression by Targeting LMNB2

    Xiao-Na L*i, Hong Yang, Tao Yang

    Oncology Research, Vol.28, No.1, pp. 41-49, 2020, DOI:10.3727/096504019X15615433287579

    Abstract In the present study, we investigated the role of miR-122 in hepatocarcinoma progression and explored the mechanism. In hepatocarcinoma tissues and cells, we used qRT-PCR to validate the miR-122 expression level. Next, we used colony formation by crystal violet staining assay to compare cell proliferation ability, and we used scratch test or Transwell assay to compare cell migration or invasion ability. We then conducted bioinformatics or luciferase reporter gene assay to prove the regulation effect of miR-122 on lamin B2 (LMNB2), and the biological function of LMNB2 was analyzed. We used nude mouse tumorigenicity assay… More >

  • Open Access

    ARTICLE

    Calcium chloride linked camel milk derived casein nanoparticles for the delivery of sorafenib in hepatocarcinoma cells

    AASTHA MITTAL1, NEELAM MAHALA1, KOWTHAVARAPU VENKATA KRISHNA2, UMA S. DUBEY1,*, SUNIL KUMAR DUBEY2,3,*

    BIOCELL, Vol.46, No.1, pp. 127-136, 2022, DOI:10.32604/biocell.2021.015932

    Abstract Sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma, is limited by its low oral bioavailability. To overcome this drawback, we have developed novel camel milk casein-derived nanoparticles as a drug delivery system. Camel milk casein is not only biocompatible on oral administration but is actually a dietary protein of pharmaceutical relevance. Casein is used because of its amphiphilic nature, self-assembling property, ability to show sustained release, and capability of encapsulating both hydrophilic and hydrophobic drugs. In this study, camel milk casein nanoparticles loaded with sorafenib were developed and characterized. Characterization of casein… More >

  • Open Access

    REVIEW

    Fundamentals of Digestive Cancers Immunology, Especially Gastric and Hepatocellular Carcinomas
    Fondamentaux de l’immunologie des Cancers Digestifs (Gastriques et Hépatocellulaires)

    Pierre-Guillaume Poureau1,2,*, Jean-Philippe Metges2

    Oncologie, Vol.23, No.1, pp. 47-59, 2021, DOI:10.32604/Oncologie.2021.15525

    Abstract Immunotherapy for digestive cancers is booming and for the first time an immune checkpoint inhibitor has been granted marketing authorization for the treatment of digestive cancer. In order to better understand the mecanism of action of these treatments, their adverse events and the escape mecansim, it is necessary to know the fundamentals of cancer immunology. The innate and adaptive immune system allows the elimination of cancer cells by direct non-specific cytotoxicity (Natural Killer cells), by the development of an adaptive cell-mediated response (dendritic cells becoming antigen presenting cells, allowing the differentiation of lymphocytes naive in… More >

Displaying 1-10 on page 1 of 5. Per Page